Anthropic Partners With 6 Pharma Orgs on Drug Development
Original: Early progress on accelerating drug development with Claude
Why This Matters
Pharma-AI integration is moving from benchmarks to live drug programs with clinical stakes.
Anthropic's life sciences team has completed early-stage research partnerships with six drug development organizations—including Bristol Myers Squibb and Generate Biomedicines—and launched its own rare disease drug discovery programs using Claude.
Anthropic's life sciences team spent several months embedded in real drug programs alongside BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. The stated goal: understand where AI actually helps across the full drug pipeline, not just molecule design. Anthropic also launched internal discovery programs, including one targeting rare childhood muscular dystrophy, where Claude handles significant scientific and operational work.
One concrete result stands out. At Generate Biomedicines, six scientists used Claude Code to redesign a component of CAR T-cell therapy—historically limited to blood cancers—so it could target solid tumors. One proposed design was roughly 70% shorter than the standard version and, in lab tests, allowed immune cells to produce about 10 times as many cancer-targeting receptors. Anthropic says the partnership work serves three goals: identifying model weaknesses to drive future improvements, creating case studies for the broader biotech industry, and producing medicines with direct patient impact—including treatments targeting food allergies, rare childhood diseases, and several cancers.
Anthropics says it plans to scale this work "substantially" and has already prioritized specific model improvements based on what it learned.